On behalf of the PVRI, the Scientific Organisers Gérald Simonneau, Marc Humbert, Stuart Rich and John Newman warmly invite you to attend our 6th Annual Drug Discovery and Development Symposium being held during the summer in Paris.
This year, the Annual Drug Discovery & Development for Pulmonary Hypertension Symposium will take place in Paris. The meeting is held annually each summer to bring leading scientists in the fields of pulmonary vascular disease, right heart failure, and clinical trial designs together with the pharmaceutical industry and regulatory authorities to help identify the most promising treatments for future development.
For each meeting, we assemble a faculty with exceptional achievements and expertise, and choose topics in areas that will influence the development of therapies immediately. Each topic will be critically reviewed by an expert panel, and open dialogue will allow your voice to be heard.
This Symposium serves as a unique forum:
The meeting by design allows for opportunities for interaction among colleagues during the meeting and at the evening reception.
Each delegate will receive a private link in an email shortly after registering, with the opportunity to book at the Symposium hotel at a reduced rate. Le Méridien Etoile is located around 30 minutes from Charles de Gaulle Airport.
The event will take place on 1 and 2 July 2019.
If you are part of government or regulatory institution and would like to attend this event, please email firstname.lastname@example.org and we will be in touch with registration details as fees are waived.
Trainees are permitted to register to this meeting at the discounted rate of $95.00, provided that you are able to supply documentation certifying your status as a trainee. Please follow the normal registration at the top of this page and one of our staff will be in touch with you.
Welcome and introduction
- Updates from work streams:
- Summary and next steps
To create an organisation where scientific, clinical and regulatory information and ideas can be openly shared, discussed and harmonised between pharma, academia and regulators worldwide to help bring promising new orphan drugs, early to this critical group of rare disease PH patients.
Priorities for the next 3 to 5 years are to:
Through worldwide collaboration, we can begin to answer the question of a global disease.